P3: Pacemaker Patient Profiling Study: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for P3: Pacemaker Patient Profiling Study (NCT00294060), a registered phase not stated study. The primary outcome is Number of Participants With Dual Chamber Devices.

2. Clinical Question

The P3 Study is described as a United States post-market study gathering information about clinical status, primary indications, device therapy choices, clinical management and outcomes for patients with implantable pacemakers. Its condition is bradycardia. The primary question recorded for the study concerns device choice at original implant: how many participants had dual chamber devices?

This framing is descriptive rather than a comparison of assigned treatments. A count can describe how often a device choice occurred in the recorded study population, but interpretation depends on knowing who was counted and the population from which they came. Those details, along with the primary outcome result, are not reported in the registry record. The record lists enrollment as 2013, but that listing alone does not establish the number included in an outcome-specific analysis.

3. Trial Design

The registry identifies the study as the Pacemaker Patient Profiling Study, titled P3: Pacemaker Patient Profiling Study, and names Medtronic Cardiac Rhythm and Heart Failure as sponsor. Its summary describes a United States post-market study intended to gather data on clinical status, primary indications, device therapy choices, clinical management and outcomes among patients with implantable pacemakers.

The registry lists the study start as 2004-03 and primary completion as 2007-11. Its status is TERMINATED. These dates and status describe the registry record; they do not establish why the study ended or whether all planned data collection and analyses were completed. A reason for termination is not reported in the registry record.

The registry lists enrollment as 2013. It does not clarify in the information available for this analysis whether that number represents a target or the final number enrolled. Nor does it report the number included in the primary outcome calculation. The record lists three outcome measures, but reports no analyses.

The study is explicitly described as not being a randomized comparison, and allocation is not stated. The registry cautions that arms are not a like-for-like control comparison. Accordingly, device groups should not be interpreted as randomized treatment groups, and differences between groups would not by themselves establish an effect caused by device choice. Details about how participants entered the study, how device choices were made, follow-up procedures, and the analysis population are not reported in the registry record.

The stated purpose is consistent with collecting information about practice and outcomes after market introduction, but the record does not provide enough design detail to characterize the sampling process or assess how representative the recorded participants may be. No protocol, sample-size justification, or rationale for the TERMINATED status is reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Only patients who received an approved study device were enrolled in the registry.

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants With Dual Chamber Devices, measured over at original implant.

The primary outcome is titled Number of Participants With Dual Chamber Devices. Its unit is participants with dual chamber devices, and its timeframe is at original implant. In plain terms, the outcome is a count of participants whose device at the original implant was dual chamber. The record describes the measure as characterizing pacemaker device choice.

A count is useful for describing how many participants fall into a specified category. It can help characterize device selection in the population studied, provided the population counted and the denominator are clear. A count alone does not indicate the share of eligible participants with that device, and it does not establish why that device was selected. The registry record does not report the observed count or a denominator for interpreting it.

The measure is binary at the participant level: each participant either meets the recorded description of having a dual chamber device or does not. The reported endpoint, however, is the number meeting that description, not an individual-level clinical benefit measure. It should therefore be read as a descriptive device-choice outcome rather than evidence about comparative effectiveness. The registry record does not report a confidence interval or other measure of uncertainty for the count.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry record identifies the primary outcome as a number of participants, with a binary participant-level meaning: participants either have a dual chamber device at original implant or they do not. The recorded summary measure is a count. The outcome is not presented as a comparison between randomized groups, and no analysis is reported.

What does a count describe?

A count states how many observed participants meet a defined criterion. It is directly interpretable only when the group being counted and the outcome definition are clear. To understand the frequency of an event or characteristic, readers also need an appropriate denominator. A count without that denominator cannot distinguish a common occurrence in a large group from the same count in a small group. The registry record does not report the primary outcome count or its denominator.

For a binary outcome, analysts may also report a proportion, a risk, or a comparison of proportions, depending on the design and question. Those measures require both the number meeting the criterion and the relevant number assessed. No such result is reported for the primary outcome in this record. No proportion, risk difference, relative measure, confidence interval, or test result should therefore be inferred from the endpoint title or the enrollment listing.

What does uncertainty add?

A confidence interval is a general statistical way to express uncertainty around an estimate. It indicates a range of values that are compatible with the observed data under the method’s assumptions. A narrow interval generally indicates greater precision than a wide interval, but an interval cannot be interpreted without the estimate, the data, and the method used to construct it. No confidence interval or interval method is reported for the primary outcome.

Statistical precision is distinct from clinical or practical importance. An estimate can be precise without answering a causal question, and an imprecise estimate can leave a wide range of plausible values. In this study, the absence of a reported result prevents assessment of either the magnitude or precision of the primary outcome.

Why does the design matter?

Randomization, when used, assigns participants to groups by chance and can support a fair comparison of assigned interventions. This registry record says the study is not a randomized comparison and that allocation is not stated. It further warns that arms are not a like-for-like control comparison. Thus, the groups cannot be treated as if their only systematic difference were device choice. Selection into a device group may relate to clinical circumstances or other characteristics; the record does not report data or analyses to evaluate those possibilities.

A descriptive device-choice count can still be informative about the participants recorded, but its scope depends on recruitment and completeness. The registry summary does not report recruitment details, the outcome denominator, missing outcome counts, or population characteristics that would help assess generalizability. Generalizability asks whether findings from those observed are informative about a broader population; it cannot be settled by the enrollment listing alone.

What can planning calculations show?

Sample-size calculations are planning illustrations, not observed results. The registry’s stated illustration assumptions describe a two-sided significance level of 0.05, equal allocation between two arms, a normal approximation, and an effect to detect defined as a stated fraction of the observed effect. Such calculations depend on the effect used as the planning target and on the assumptions of the calculation. The registry record does not report the observed primary effect needed to interpret those illustrations, nor does it report a study-specific sample-size justification.

A calculated sample size under assumptions does not show that a study had a particular probability of detecting an effect after the study is complete. That post hoc interpretation is not warranted by a planning calculation. The assumptions also do not establish that the actual study used equal allocation, a normal approximation, or the stated significance level in its analysis; they describe the planning illustration only. No inferential analysis is reported in the registry record.

How should event counts be read?

Event counts require a population at risk and a defined observation period to be interpreted as frequencies or rates. The adverse-event record lists zero at risk and zero affected for both serious and other events in the Pacing Patients group. Those entries do not provide a meaningful denominator for estimating event occurrence. The death count is not reported in the registry record. In general, a zero event count in a group with no recorded participants at risk is not evidence of zero risk.

Over-dispersion is a general concern when count data vary more than a chosen statistical model expects; ignoring it can make uncertainty estimates misleading. The primary outcome is a count of participants meeting a binary criterion, and no model or inferential analysis is reported. There is therefore no basis to assess whether over-dispersion was relevant or whether any model accounted for it. More broadly, the registry record does not state an analysis plan, so model choice, covariate adjustment, handling of missing data, and inferential procedures are not reported.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Pacing Patients")
n      <- c(2013)
events <- c(1684)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Pacing Patients  2013  1684  83.7  82.0  85.2  82.0  85.2  82.0  85.2

11. Multiplicity, Missing Data and Analysis Populations

The registry lists three outcome measures, while the primary outcome is identified as the number of participants with dual chamber devices at original implant. The record does not report analyses. It also does not explain how the primary outcome was distinguished from other outcomes for inference, whether multiple hypotheses were tested, or whether any adjustment for multiple testing was planned or used. A multiplicity strategy is not reported in the registry record.

Multiplicity matters when several outcomes or comparisons are examined because repeated testing can increase the chance of apparently notable results arising by chance. This is a general statistical concern, not a claim that such testing occurred in this study. With no posted analyses, it is not possible to assess how many comparisons were conducted or how their interpretation was handled.

Missing-data methods and the number of participants with missing primary outcome information are not reported in the registry record. The registry lists enrollment as 2013, but does not report the outcome-specific denominator. Consequently, the completeness of the primary outcome and the relationship between enrollment and analysis cannot be assessed. No imputation, exclusion rule, or sensitivity analysis is reported.

The analysis population is also not described. The record does not state whether the primary outcome was assessed among all enrolled participants, a subset with available device information, or another defined group. It does not provide a protocol-based analysis population or criteria for inclusion in the analysis. These gaps limit interpretation of the outcome count and any attempt to assess selection or missingness. No assumptions about missingness or analysis populations can be attributed to the study from the registry record.

12. What the Result Does, and Does Not, Mean

The primary outcome describes a device-choice characteristic at original implant: the number of participants with dual chamber devices. A reported count, together with a clearly defined denominator and population, could describe the observed study group. The registry record does not report those outcome results, so the number and frequency cannot be interpreted from the posted information.

The study summary says that the P3 Study was intended to gather information on clinical status, primary indications, device therapy choices, clinical management and outcomes among patients with implantable pacemakers. That purpose does not itself demonstrate that every topic was measured, that data were complete, or that any particular outcome was favorable. The record lists three outcome measures, but reports zero analyses.

The study is not a randomized comparison, allocation is not stated, and the registry warns that arms are not a like-for-like control comparison. Accordingly, the record does not establish that device choice caused any difference in clinical status or outcomes. It also does not provide an estimate of the comparative effects of device strategies. Any claim about benefit, harm, or superiority would go beyond the registry results reported.

The adverse-event entries do not establish safety or absence of events. For Pacing Patients, the record lists zero at risk and zero affected for serious and other events, while deaths are not reported. With zero at risk, the event counts cannot be interpreted as rates or as evidence that events did not occur.

The enrollment listing and the TERMINATED status are descriptive registry information. Neither resolves the missing primary result, reveals why the study ended, nor establishes how representative the participants were. Those details are not reported in the registry record. The sound conclusion is therefore limited: the study’s stated objective and endpoint are identifiable, but the available record does not provide the results needed to quantify the endpoint or draw comparative conclusions.

13. Why This Trial Matters Statistically

This study raises a useful statistical distinction between describing clinical practice and estimating the effect of a treatment. The registry describes a post-market project intended to gather information about device choices and patient outcomes. Its primary endpoint counts participants with dual chamber devices at original implant, which is a descriptive measure of device choice. Without a randomized comparison or a suitable comparison design, that measure should not be read as a treatment-effect estimate.

It also illustrates why an enrollment figure is not a substitute for outcome reporting. The registry lists enrollment as 2013, but does not report the primary outcome count, denominator, or analysis population. Readers therefore cannot assess how much information the endpoint contains or how precisely it is estimated. A count needs context to be interpretable; the endpoint label alone is not a result.

The record’s status and reporting gaps also matter for transparency. It is marked TERMINATED, but the reason is not reported in the registry record. Three outcome measures are listed and zero analyses are reported. These registry entries do not explain what happened during study conduct, but they identify limits on what can be learned from the registry entry.

Finally, the adverse-event listing shows why event counts must be read alongside the population at risk. Zero event entries alongside zero participants at risk do not provide an estimate of event frequency. This is a general lesson in interpreting safety summaries: denominators and observation context are essential. Overall, the study record is informative about the intended descriptive question, while its posted results are insufficient for quantitative or causal conclusions.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation is the absence of a reported primary outcome result. The registry names the count of participants with dual chamber devices at original implant, but does not give the count, denominator, or uncertainty estimate. This prevents quantitative interpretation of the stated primary endpoint.

Although the registry lists enrollment as 2013, it does not report how many participants contributed to the primary outcome or whether the enrollment listing is a target or final enrollment figure. Participant characteristics, eligibility details, recruitment procedures, and the analysis population are not reported in the registry record. These omissions make it difficult to judge completeness or generalizability.

The registry describes the study as nonrandomized, says allocation is not stated, and cautions that arms are not a like-for-like control comparison. It does not report an adjustment strategy or details that would support a causal comparison. The record therefore cannot establish whether observed differences between any groups reflect device choice or other factors.

The study is marked TERMINATED, but the reason is not reported in the registry record. The record lists three outcome measures and zero analyses, and does not report a statistical analysis plan, sample-size justification, multiplicity approach, missing-data method, or interim analyses. Their absence from the record does not establish whether these activities occurred outside it.

Finally, the adverse-event entries list zero at risk and zero affected in the Pacing Patients group for serious and other events, while deaths are not reported. These data do not permit meaningful event-rate interpretation. Together, the missing outcome results and limited design and analysis detail sharply restrict what the registry record can support.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: P3: Pacemaker Patient Profiling Study — NCT00294060.
• Registry record last updated 2011-05-06; status last verified 2011-04.
• Results first posted 2011-05-06.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The P3 Pacemaker Patient Profiling Study is a United States post-market study sponsored by Medtronic Cardiac Rhythm and Heart Failure. The registry lists bradycardia as the condition, enrollment as 2013, a start of 2004-03, primary completion of 2007-11, and status TERMINATED. Its summary describes gathering information on clinical status, primary indications, device therapy choices, clinical management and outcomes among patients with implantable pacemakers.

The primary outcome is the number of participants with dual chamber devices at original implant. The registry lists three outcome measures and zero analyses, but does not report the primary outcome result or its denominator. The study is not a randomized comparison, allocation is not stated, and arms are not described as like-for-like controls. The reason for termination, analysis population, missing-data methods, and statistical analysis plan are not reported in the registry record. The posted information identifies the study question but does not support a quantitative estimate or causal conclusion.